Vor Biopharma (VOR) Accounts Payables (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Accounts Payables data on file, last reported at $1.0 million in Q1 2026.

• Quarterly Accounts Payables fell 72.05% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 72.05% YoY) and the FY2025 annual result came in at $5.1 million, up 240.66% from the prior year.
• Accounts Payables retreated to $1.0 million in Q1 2026 per VOR's latest filing, from $5.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $5.1 million in Q4 2025 and bottomed at $669000.0 in Q2 2025.
• The 5-year median for Accounts Payables is $1.3 million (2024), against an average of $1.8 million.
• The widest annual swing landed in 2025, when Accounts Payables soared 240.66%; it then slumped 72.05% in 2026.
• Tracing VOR's Accounts Payables over 5 years: stood at $1.8 million in 2022, then slumped by 54.01% to $815000.0 in 2023, then jumped by 84.66% to $1.5 million in 2024, then soared by 240.66% to $5.1 million in 2025, then tumbled by 79.66% to $1.0 million in 2026.
• Per Business Quant, the three latest VOR Accounts Payables figures stand at $1.0 million (Q1 2026), $5.1 million (Q4 2025), and $885000.0 (Q3 2025).

Peer Comparison